Clinical Trial Update: Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating sorafenib (BAY43-9006) in combination with docetaxel (Taxotere) for prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Nexavar (Sorafenib)
• Taxotere (docetaxel)

Snippet

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Conditions: Primary Disease, Prostate Cancer | Phase 1 | Status: COMPLETED